A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

Clinical trial NCT02296476 · TERMINATED

Trial details

NCT number: NCT02296476
Sponsor: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma Multiforme

Start date: 2014-10-29
Primary completion: 2015-10-20
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.